Mylan (MYL -0.6%) says its subsidiary, Mylan Pharmaceuticals, has received final FDA approval for its Abbreviated New Drug Application for Candesartan Cilexetil and Hydrochlorothiazide Tablets, the generic version of AstraZeneca's (AZN) Atacand HCT, which is indicated indicated for the treatment of hypertension. Mylan will begin shipping all approved strengths immediately.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Fri, 1:30PM)
at Zacks.com (Fri, 8:33AM)
at Investor's Business Daily (Tue, 2:59PM)
at Investor's Business Daily (Mon, 2:59PM)
at Investor's Business Daily (Feb 2, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs